FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800933213> ?p ?o ?g. }

• W2800933213 endingPage "333" @default.
• W2800933213 startingPage "324" @default.
• W2800933213 abstract "Mirabegron is an established treatment alternative to antimuscarinic therapy for patients with overactive bladder (OAB), as shown by efficacy and tolerability data from phase III trials.To assess efficacy and tolerability of mirabegron 50mg versus antimuscarinic monotherapies and combination therapies.Systematic literature review and network meta-analysis of randomised controlled trials (2000-2017) assessing eligible treatments for OAB.Efficacy assessments included micturition frequency, urgency urinary incontinence, dry rate, and 50% reduction in incontinence. Tolerability assessments included dry mouth, constipation, blurred vision, and hypertension.A total of 64 studies (n=46 666) were included in the network meta-analysis. Mirabegron 50mg was significantly more efficacious than placebo for all efficacy endpoints. Comparable overall efficacy was observed for mirabegron 50mg versus most active treatments, but solifenacin 10mg monotherapy and solifenacin 5mg plus mirabegron 25 or 50mg in combination were more efficacious for some/all outcomes. Mirabegron 50mg was significantly better tolerated regarding dry mouth, constipation, and urinary retention than 21/22, 9/20, and 7/10 active comparators, respectively; similar overall tolerability was observed between mirabegron 50mg and all treatments (including placebo) for the remaining endpoints. Limitations of the study included between-trial variations in the definition of certain endpoints and heterogeneity of the available data (eg, number of studies and patients assessed) for comparator treatments across different endpoints.The relief of key OAB symptoms produced by mirabegron 50mg is significantly better than placebo, and similar to a range of common antimuscarinics, with the benefit of significantly fewer bothersome anticholinergic side effects such as dry mouth. Combination treatment of solifenacin 5mg plus mirabegron 25 or 50mg appears to provide an efficacy benefit compared with mirabegron 50mg, with the expected side effects of individual antimuscarinics.This study assessed the efficacy and tolerability of different drug treatments for OAB. Mirabegron 50mg was as effective as antimuscarinic therapy, with fewer common, bothersome side effects such as dry mouth, constipation, and urinary retention. Combination treatment of solifenacin 5mg plus mirabegron 25 or 50mg was more effective than mirabegron 50mg alone, but with more anticholinergic side effects." @default.
• W2800933213 created "2018-05-17" @default.
• W2800933213 creator A5024171925 @default.
• W2800933213 creator A5028834947 @default.
• W2800933213 creator A5064197337 @default.
• W2800933213 creator A5073241338 @default.
• W2800933213 creator A5080266362 @default.
• W2800933213 creator A5088119779 @default.
• W2800933213 creator A5090695716 @default.
• W2800933213 creator A5090982960 @default.
• W2800933213 date "2018-09-01" @default.
• W2800933213 modified "2023-10-11" @default.
• W2800933213 title "Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis" @default.
• W2800933213 cites W1968860914 @default.
• W2800933213 cites W1972477468 @default.
• W2800933213 cites W1976101513 @default.
• W2800933213 cites W1986758727 @default.
• W2800933213 cites W2009611159 @default.
• W2800933213 cites W2067945145 @default.
• W2800933213 cites W2071052332 @default.
• W2800933213 cites W2082897746 @default.
• W2800933213 cites W2096360296 @default.
• W2800933213 cites W2098923148 @default.
• W2800933213 cites W2107806473 @default.
• W2800933213 cites W2110991424 @default.
• W2800933213 cites W2111116907 @default.
• W2800933213 cites W2128421946 @default.
• W2800933213 cites W2131173377 @default.
• W2800933213 cites W2134928141 @default.
• W2800933213 cites W2144564072 @default.
• W2800933213 cites W2150043453 @default.
• W2800933213 cites W2212452621 @default.
• W2800933213 cites W2286258673 @default.
• W2800933213 cites W2293202443 @default.
• W2800933213 cites W2332614769 @default.
• W2800933213 cites W2581612511 @default.
• W2800933213 cites W2587662747 @default.
• W2800933213 cites W2606250578 @default.
• W2800933213 doi "https://doi.org/10.1016/j.eururo.2018.03.020" @default.
• W2800933213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29699858" @default.
• W2800933213 hasPublicationYear "2018" @default.
• W2800933213 type Work @default.
• W2800933213 sameAs 2800933213 @default.
• W2800933213 citedByCount "131" @default.
• W2800933213 countsByYear W28009332132018 @default.
• W2800933213 countsByYear W28009332132019 @default.
• W2800933213 countsByYear W28009332132020 @default.
• W2800933213 countsByYear W28009332132021 @default.
• W2800933213 countsByYear W28009332132022 @default.
• W2800933213 countsByYear W28009332132023 @default.
• W2800933213 crossrefType "journal-article" @default.
• W2800933213 hasAuthorship W2800933213A5024171925 @default.
• W2800933213 hasAuthorship W2800933213A5028834947 @default.
• W2800933213 hasAuthorship W2800933213A5064197337 @default.
• W2800933213 hasAuthorship W2800933213A5073241338 @default.
• W2800933213 hasAuthorship W2800933213A5080266362 @default.
• W2800933213 hasAuthorship W2800933213A5088119779 @default.
• W2800933213 hasAuthorship W2800933213A5090695716 @default.
• W2800933213 hasAuthorship W2800933213A5090982960 @default.
• W2800933213 hasBestOaLocation W28009332131 @default.
• W2800933213 hasConcept C126322002 @default.
• W2800933213 hasConcept C126894567 @default.
• W2800933213 hasConcept C142724271 @default.
• W2800933213 hasConcept C197934379 @default.
• W2800933213 hasConcept C204787440 @default.
• W2800933213 hasConcept C27081682 @default.
• W2800933213 hasConcept C2777912814 @default.
• W2800933213 hasConcept C2778164427 @default.
• W2800933213 hasConcept C2778375690 @default.
• W2800933213 hasConcept C2778941218 @default.
• W2800933213 hasConcept C2779502394 @default.
• W2800933213 hasConcept C2781112942 @default.
• W2800933213 hasConcept C71924100 @default.
• W2800933213 hasConceptScore W2800933213C126322002 @default.
• W2800933213 hasConceptScore W2800933213C126894567 @default.
• W2800933213 hasConceptScore W2800933213C142724271 @default.
• W2800933213 hasConceptScore W2800933213C197934379 @default.
• W2800933213 hasConceptScore W2800933213C204787440 @default.
• W2800933213 hasConceptScore W2800933213C27081682 @default.
• W2800933213 hasConceptScore W2800933213C2777912814 @default.
• W2800933213 hasConceptScore W2800933213C2778164427 @default.
• W2800933213 hasConceptScore W2800933213C2778375690 @default.
• W2800933213 hasConceptScore W2800933213C2778941218 @default.
• W2800933213 hasConceptScore W2800933213C2779502394 @default.
• W2800933213 hasConceptScore W2800933213C2781112942 @default.
• W2800933213 hasConceptScore W2800933213C71924100 @default.
• W2800933213 hasIssue "3" @default.
• W2800933213 hasLocation W28009332131 @default.
• W2800933213 hasLocation W28009332132 @default.
• W2800933213 hasOpenAccess W2800933213 @default.
• W2800933213 hasPrimaryLocation W28009332131 @default.
• W2800933213 hasRelatedWork W2319053117 @default.
• W2800933213 hasRelatedWork W2323954177 @default.
• W2800933213 hasRelatedWork W2337928325 @default.
• W2800933213 hasRelatedWork W2509856222 @default.
• W2800933213 hasRelatedWork W2780028233 @default.
• W2800933213 hasRelatedWork W2800933213 @default.
• W2800933213 hasRelatedWork W3108460588 @default.

• next